David J. Andorsky, MD
Medical Oncologist / Hematologist
About David J. Andorsky, MD
Dr. David Andorsky is a board-certified medical oncologist and hematologist. His practice emphasis includes breast, colorectal, lung, and urological cancers as well as blood cancers such as leukemia, lymphoma, and multiple myeloma. Dr. Andorsky is an Associate Chair for US Oncology Hematology Research and sits on the Rocky Mountain Cancer’s Research Executive Committee. He is principal investigator for many clinical research trials at RMCC. This engagement allows him to stay abreast of the latest treatment options to ensure his patients have the most up-to-date therapies available to them. He is a member of the US Oncology Pathways Task Force, which sets policies for best cancer treatment practices across the entire US Oncology network.
Dr. Andorsky believes in a collaborative approach to caring for his patients. He is the chair of the RMCC Boulder general cancer conference and gastrointestinal malignancies conference. As an active participant in the weekly breast cancer conference, he presents and reviews cases with other cancer specialists, such as surgeons, radiologists, pathologists and radiation oncologists. This group of experts share a vast expanse of knowledge that is used to tailor treatment plans for each patient.
Clinical Care Expertise
- Breast Cancer
- Blood Cancers
- Multiple Myeloma
- Gastrointestinal Cancers
- Colorectal Cancer
- Lung Cancer
- Genitourinary Cancers
- Adrenal Cancer
- Bladder Cancer
- Kidney Cancer
- Penile Cancer
- Prostate Cancer
- Testicular Cancer
Hematology & Oncology, UCLA Medical Center, Los Angeles, CA
Internal Medicine, Brigham and Women’s Hospital, Boston, MA
Harvard Medical School, Boston, MA
Patient Care Philosophy
My goal is to deliver individualized care of the highest quality to each of my patients. I strive to provide care based on state-of-the-art medical science while remaining focused on all aspects of the patient’s experience—physical, emotional, psychological, and spiritual.
I encourage my patients to participate in clinical research trials when it meets their needs. This often allows patients to have access to the newest and most promising treatments before they are widely available.
I welcome all patients and have expertise in treating all types of cancer. I have particular expertise in treating blood cancers (such as lymphoma, myeloma, and leukemia) and breast cancer.
American Society of Clinical Oncology
American Society of Hematology
Boulder Community Hospital Blood Management Committee
Boulder Community Hospital Ethics Committee
Boulder Community Health Medical Executive Committee
Rocky Mountain Cancer Centers Research Executive Committee
US Oncology Hematology Research Committee, Associate Chair
Sharman J, Kabadi SM, Clark J, Andorsky D. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021 Feb;192(4):737-746.
Burke JM, Morschhauser F, Andorsky D, Lee C, Sharman JP. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin. Expert Rev Clin Pharmacol. 2020 Oct;13(10):1073-1083.
Furutani E, Shah AS, Zhao Y, Andorsky D, Dedeoglu F, Geddis A, Zhou Y,
Libermann TA, Myers KC, Shimamura A. Inflammatory manifestations in patients with Shwachman-Diamond syndrome: A novel phenotype. Am J Med Genet A. 2020 Apr 15.
Arch JJ, Fishbein JN, Ferris MC, Mitchell JL, Levin ME, Slivjak ET, Andorsky DJ, Kutner JS. Acceptability, Feasibility, and Efficacy Potential of a Multimodal Acceptance and Commitment Therapy Intervention to Address Psychosocial and Advance Care Planning Needs among Anxious and Depressed Adults with MetastaticCancer. J Palliat Med. 2020 Jan 6.
Pettengell R, Długosz-Danecka M, Andorsky D, Belada D, Georgiev P, Quick D, Singer JW, Singh SB, Pallis A, Egorov A, Salles G. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). British Journal of Haematology, 2020, 188, 240–248.
David Andorsky, Rebecca J Chan, Jamyia Clark, Bianca Ruzicka, Nicholas James Robert, and Farrukh T. Awan. Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting. Blood 2019 133:2180 (abstract)
Jeff P. Sharman, David Andorsky, Jason M. Melear, Sudhir Manda, Bertrand M. Anz III, Kathryn S. Kolibaba, Habte A Yimer, John M Burke, Suzanne R. Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Abdullah Al Masud, Todd Zimmerman, Jacqueline Nielsen, Tamas Vizkelety, Dingfeng Jiang, and Ian W. Flinn, MD. Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study. Blood 2019 133: 3042 (abstract)
Andorsky DJ, Kolibaba KS, Assouline S, Forero-Torres A, Jones V, Klein LM, Patel-Donnelly, Smith M, Ye W, Shi W, Yasenchak CA, Sharman JP. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2019 Jan;184(2):215-222.
Arch JJ, Mitchell JL, Genung SR, Fisher R, Andorsky DJ, Stanton AL. A randomized controlled trial of a group acceptance-based intervention for cancer survivors experiencing anxiety at re-entry ('Valued Living'): study protocol. BMC Cancer. 2019 Jan 18;19(1):89.
Jeff Sharman, Shaum Kabadi, Jamyia Clark, E Susan Amirian and David J. Andorsky. Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study. Blood 2018 132:4163 (abstract)
Gilles Andre Salles, Wojciech Jurczak, David J. Andorsky, Donald P. Quick, Jack W. Singer, Simran Singh Lixia Wang, Anton Egorov, Christine Gabarroca and Ruth Pettengell. Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation. Blood 2018 132:4189 (abstract)
Loretta J. Nastoupil, Fontanet Bijou, Vincent Ribrag, Julio C. Chavez, Thomas E. Witzig, David J. Andorsky, Leonard M. Klein, Daniel Greenwald, Armando Santoro, Paolo Corradini, Ian W. Flinn, Randeep Sangha, Vaishalee P. Kenkre, Shailaja Uttamsingh, Patrick R. Hagner, Anita K. Gandhi, Tianlei Chen, Kristen Hege, Michael Pourdehnad and John Kuruvilla. Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma. Blood 2018 132:1602 (abstract)
David Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason M. Melear, Heather Dawn Brooks, Suzanne R. Fanning, Kathryn S. Kolibaba, Frederick Lansigan, Chris Reynolds, Jiahui Li, Dongfang Liu, Mary Llorente, Justin L. Ricker, Jeff Porter Sharman. Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL. J Clin Oncol 36, 2018 (suppl; abstr 7516)
Goldberg SL, Cortes J, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017;92:1214–1223.
John M. Burke, David J. Andorsky, Abdulraheem Yacoub, Jason Melear, Morton Coleman, Kathryn Kolibaba, Heather Brooks, Jacob Bitran, Suzanne Fanning, Frederick Lansigan, Justin L. Ricker, Kenneth Foon, Mary Llorente, Jiahui Li, Jeff Sharman. Phase IIB study of lenalidomide plus rituximab followed by maintenance relapsed or refractory NHL: Analysis of follicular lymphoma patients. European Hematology Association (abstract) Jun 24, 2017; 181921
Coleman, M., Andorsky, D. J., Yacoub, A., Melear, J. M., Kolibaba, K. S., Brooks, H. D., Bitran, J. D., Fanning, S. R., Lansigan, F., Ricker, J. L., Foon, K. A., Llorente, M., Li, J., and Sharman, J. P. (2017) Phase IIB study of lenalidomide plus rituximab followed by maintenance relapsed or refractory NHL: Analysis of marginal zone lymphoma. Hematological Oncology, 35(S2): 148
David Jacob Andorsky, Abdulraheem Yacoub, Jason M. Melear, Morton Coleman, Kathryn S. Kolibaba, Heather Dawn Brooks, Jacob D. Bitran, Suzanne R. Fanning, Frederick Lansigan, Justin L. Ricker, Kenneth A. Foon, Dongfang Liu, Mary Llorente, Jiahui Li, Jeff Porter Sharman, and MAGNIFY Trial Investigators. Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL). Journal of Clinical Oncology 2017 35:15_suppl, 7502-7502
Sarit E. Assouline, Kathryn S. Kolibaba, Leonard M. Klein, Morton Coleman, Mitchell Reed Smith, Esteban Abella-Dominicis, Wei Ye, Wen Shi, David Jacob Andorsky, and Jeff Porter Sharman. Results of a phase II trial of efficacy and safety of entospletinib (ENTO) in patients with lymphoplasmacytoid lymphoma/Waldenstrom's macroglubulinemia (LPL/WM). J Clin Oncol 2017 35:15_suppl, 7565-7565
David J. Andorsky, Abdulraheem Yacoub, Jacob D. Bitran, Jason Melear, Heather D. Brooks, Kenneth A. Foon, Syed Rizvi, Mary Llorente, Jiahui Li, and Jeff P. Sharman. MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma. Blood Dec 2016 128(22): 1798.
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Etienne, Franck E Nicolini, Philipp le Coutre, Richard E Clark, Leif Stenke, David Andorsky, Vivian Oehler, Stephanie Lustgarten, Victor M Rivera, Timothy Clackson, Frank G Haluska, Michele Baccarani, Jorge E Cortes, François Guilhot, Andreas Hochhaus, Timothy Hughes, Hagop M Kantarjian, Neil P Shah, Moshe Talpaz, Michael W Deininger. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial, The Lancet Oncology 2016 May 2016; 17(5),612-621.